Revolution Medicines Key Executives
This section highlights Revolution Medicines's key executives, including their titles and compensation details.
Find Contacts at Revolution Medicines
(Showing 0 of )
Revolution Medicines Earnings
This section highlights Revolution Medicines's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-27 | N/A | N/A |
| Read Transcript | Q3 | 2024 | 2024-11-06 | $-0.89 | $-0.94 |
| Read Transcript | Q2 | 2024 | 2024-08-11 | N/A | N/A |
| Read Transcript | Q1 | 2024 | 2024-05-08 | $-0.75 | $-0.70 |
| Read Transcript | Q4 | 2023 | 2024-02-26 | $-0.86 | $-1.14 |
| Read Transcript | Q3 | 2023 | 2023-11-06 | $-1.01 | $-0.99 |
| Read Transcript | Q2 | 2023 | 2023-08-08 | $-0.83 | $-0.92 |
| Read Transcript | Q1 | 2023 | 2023-05-08 | $-0.84 | $-0.72 |
Financial Statements
Access annual & quarterly financial statements for Revolution Medicines, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $- | $11.58M | $35.38M | $29.39M | $42.98M |
| Cost of Revenue | $- | $- | $9.66M | $7.33M | $132.25M |
| Gross Profit | $- | $11.58M | $25.72M | $22.06M | $-89.27M |
| Gross Profit Ratio | 0.00% | 100.00% | 72.71% | 75.05% | -207.68% |
| Research and Development Expenses | $592.23M | $423.14M | $253.07M | $186.95M | $132.25M |
| General and Administrative Expenses | $97.30M | $75.62M | $40.59M | $30.45M | $21.43M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $97.30M | $75.62M | $40.59M | $30.45M | $21.43M |
| Other Expenses | $- | $- | $- | $- | $- |
| Operating Expenses | $689.52M | $498.76M | $293.66M | $217.40M | $153.68M |
| Cost and Expenses | $- | $498.76M | $293.66M | $217.40M | $153.68M |
| Interest Income | $86.88M | $47.48M | $9.15M | $929.00K | $2.24M |
| Interest Expense | $- | $303.00K | $- | $12.00K | $71.00K |
| Depreciation and Amortization | $- | $9.31M | $9.66M | $7.33M | $6.54M |
| EBITDA | $-689.52M | $-430.58M | $-239.47M | $-179.75M | $-101.91M |
| EBITDA Ratio | - | -3718.32% | -676.85% | -611.59% | -237.10% |
| Operating Income | $-689.52M | $-487.19M | $-258.28M | $-188.01M | $-110.70M |
| Operating Income Ratio | - | -4207.12% | -730.01% | -639.70% | -257.54% |
| Total Other Income Expenses Net | $88.68M | $47.29M | $9.15M | $917.00K | $2.17M |
| Income Before Tax | $-600.85M | $-439.89M | $-249.12M | $-187.09M | $-108.53M |
| Income Before Tax Ratio | - | -3798.71% | -704.14% | -636.58% | -252.50% |
| Income Tax Expense | $753.00K | $-3.52M | $-420.00K | $-7.32M | $-371.00K |
| Net Income | $-600.09M | $-436.37M | $-248.71M | $-179.77M | $-108.16M |
| Net Income Ratio | - | -3768.28% | -702.95% | -611.67% | -251.63% |
| EPS | $-3.58 | $-3.86 | $-3.08 | $-2.47 | $-1.62 |
| EPS Diluted | $-3.58 | $-3.86 | $-3.08 | $-2.47 | $-1.62 |
| Weighted Average Shares Outstanding | 167.74M | 113.15M | 80.63M | 72.81M | 66.60M |
| Weighted Average Shares Outstanding Diluted | 167.74M | 113.15M | 80.63M | 72.81M | 66.60M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $742.00K | $- | $3.82M | $7.01M | $15.33M | $3.36M | $9.12M | $7.58M | $9.46M | $1.10M | $8.70M | $10.13M | $8.75M | $12.66M | $10.03M | $11.55M |
| Cost of Revenue | $- | $- | $12.78M | $118.02M | $2.86M | $2.15M | $1.77M | $2.53M | $2.60M | $69.45M | $2.33M | $2.29M | $2.06M | $46.47M | $45.94M | $40.86M | $37.01M | $34.87M | $32.92M | $27.46M |
| Gross Profit | $- | $- | $-12.78M | $-118.02M | $-2.12M | $-2.15M | $2.05M | $4.48M | $12.73M | $-66.10M | $6.78M | $5.29M | $7.40M | $-45.37M | $-37.24M | $-30.73M | $-28.25M | $-22.21M | $-22.89M | $-15.91M |
| Gross Profit Ratio | - | 0.00% | - | - | -285.18% | - | 53.63% | 63.89% | 83.05% | -1969.58% | 74.40% | 69.78% | 78.20% | -4120.98% | -428.12% | -303.30% | -322.88% | -175.42% | -228.36% | -137.81% |
| Research and Development Expenses | $188.10M | $151.75M | $134.93M | $118.02M | $146.87M | $107.73M | $97.98M | $68.95M | $66.13M | $69.45M | $61.00M | $56.49M | $53.68M | $46.47M | $45.94M | $40.86M | $37.01M | $34.87M | $32.92M | $27.46M |
| General and Administrative Expenses | $28.21M | $23.96M | $21.71M | $22.84M | $32.24M | $15.51M | $14.64M | $13.22M | $10.91M | $10.43M | $10.20M | $9.04M | $8.69M | $7.79M | $7.30M | $6.67M | $5.83M | $5.34M | $5.09M | $5.17M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $-1.24M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $28.21M | $23.96M | $21.71M | $22.84M | $31.00M | $15.51M | $14.64M | $13.22M | $10.91M | $10.43M | $10.20M | $9.04M | $8.69M | $7.79M | $7.30M | $6.67M | $5.83M | $5.34M | $5.09M | $5.17M |
| Other Expenses | $- | $- | $-12.78M | $-118.02M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Operating Expenses | $216.31M | $175.71M | $143.87M | $22.84M | $177.87M | $123.25M | $112.62M | $82.17M | $77.04M | $79.89M | $71.20M | $65.53M | $62.37M | $54.26M | $53.23M | $47.53M | $42.83M | $40.21M | $38.01M | $32.63M |
| Cost and Expenses | $216.31M | $175.71M | $156.64M | $140.86M | $180.72M | $123.25M | $112.62M | $82.17M | $77.04M | $79.89M | $71.20M | $65.53M | $62.37M | $54.26M | $53.23M | $47.53M | $42.83M | $40.21M | $38.01M | $32.63M |
| Interest Income | $21.23M | $20.41M | $21.49M | $23.76M | $18.98M | $10.95M | $10.50M | $7.06M | $5.08M | $2.91M | $867.00K | $302.00K | $237.00K | $223.00K | $236.00K | $233.00K | $252.00K | $347.00K | $730.00K | $909.00K |
| Interest Expense | $- | $- | $- | $- | $9.29M | $- | $- | $- | $- | $- | $867.00K | $302.00K | $- | $- | $- | $12.00K | $14.00K | $17.00K | $19.00K | $21.00K |
| Depreciation and Amortization | $3.39M | $- | $1.71M | $1.51M | $2.86M | $2.15M | $1.77M | $2.53M | $2.60M | $2.43M | $2.33M | $2.29M | $2.06M | $1.75M | $1.84M | $1.68M | $1.70M | $1.63M | $1.67M | $1.54M |
| EBITDA | $-212.92M | $-175.71M | $-154.93M | $-139.35M | $-158.34M | $-121.10M | $-107.02M | $-72.62M | $-54.03M | $-71.19M | $-59.76M | $-55.66M | $-50.61M | $-51.19M | $-42.46M | $-35.49M | $-32.13M | $-25.57M | $-25.58M | $-18.63M |
| EBITDA Ratio | - | - | - | - | -21339.08% | - | -2798.74% | -1035.41% | -352.45% | -2121.36% | -655.50% | -734.48% | -535.03% | -4649.32% | -488.14% | -350.27% | -367.14% | -201.99% | -255.19% | -161.35% |
| Operating Income | $-216.31M | $-175.71M | $-156.64M | $-140.86M | $-179.98M | $-123.25M | $-108.80M | $-75.16M | $-61.71M | $-76.53M | $-62.09M | $-57.95M | $-52.91M | $-53.16M | $-44.53M | $-37.40M | $-34.08M | $-27.55M | $-27.98M | $-21.08M |
| Operating Income Ratio | - | - | - | - | -24256.47% | - | -2845.11% | -1071.53% | -402.52% | -2280.48% | -681.10% | -764.70% | -559.33% | -4828.61% | -512.01% | -369.13% | -389.44% | -217.61% | -279.14% | -182.59% |
| Total Other Income Expenses Net | $20.99M | $19.42M | $23.41M | $24.86M | $18.79M | $10.95M | $10.50M | $7.06M | $5.08M | $2.91M | $867.00K | $302.00K | $237.00K | $223.00K | $236.00K | $221.00K | $238.00K | $330.00K | $711.00K | $888.00K |
| Income Before Tax | $-195.32M | $-156.29M | $-133.23M | $-116.00M | $-161.19M | $-112.30M | $-98.30M | $-68.10M | $-56.63M | $-73.63M | $-61.22M | $-57.65M | $-52.68M | $-52.94M | $-44.30M | $-37.18M | $-33.84M | $-27.22M | $-27.27M | $-20.19M |
| Income Before Tax Ratio | - | - | - | - | -21724.26% | - | -2570.55% | -970.89% | -369.41% | -2193.86% | -671.59% | -760.72% | -556.83% | -4808.36% | -509.30% | -366.95% | -386.72% | -215.00% | -272.05% | -174.90% |
| Income Tax Expense | $-753.00K | $- | $- | $- | $343.00K | $3.87M | $-1.77M | $-9.59M | $-123.00K | $-297.00K | $-867.00K | $-302.00K | $-1.82M | $223.00K | $236.00K | $233.00K | $362.00K | $347.00K | $-58.00K | $-675.00K |
| Net Income | $-194.57M | $-156.29M | $-133.23M | $-116.00M | $-161.54M | $-108.43M | $-98.30M | $-58.51M | $-56.51M | $-73.33M | $-60.35M | $-57.34M | $-52.68M | $-52.94M | $-44.30M | $-37.18M | $-34.20M | $-27.22M | $-27.21M | $-19.52M |
| Net Income Ratio | - | - | - | - | -21770.49% | - | -2570.55% | -834.13% | -368.60% | -2185.01% | -662.08% | -756.73% | -556.83% | -4808.36% | -509.30% | -366.95% | -390.86% | -215.00% | -271.47% | -169.05% |
| EPS | $-1.12 | $-0.94 | $-0.81 | $-0.70 | $-1.14 | $-0.99 | $-0.92 | $-0.62 | $-0.63 | $-0.87 | $-0.81 | $-0.77 | $-0.71 | $-0.72 | $-0.60 | $-0.53 | $-0.52 | $-0.42 | $-0.46 | $-0.67 |
| EPS Diluted | $-1.12 | $-0.94 | $-0.81 | $-0.70 | $-1.14 | $-0.99 | $-0.92 | $-0.62 | $-0.63 | $-0.87 | $-0.81 | $-0.77 | $-0.71 | $-0.72 | $-0.60 | $-0.53 | $-0.52 | $-0.42 | $-0.46 | $-0.67 |
| Weighted Average Shares Outstanding | 167.74M | 166.84M | 165.14M | 164.73M | 141.18M | 109.23M | 106.88M | 94.83M | 89.16M | 84.69M | 74.28M | 74.16M | 73.82M | 73.54M | 73.40M | 70.42M | 66.32M | 64.89M | 58.75M | 29.30M |
| Weighted Average Shares Outstanding Diluted | 167.74M | 166.84M | 165.14M | 164.73M | 141.18M | 109.23M | 106.88M | 94.83M | 89.16M | 84.69M | 74.28M | 74.16M | 73.83M | 73.54M | 73.40M | 70.42M | 66.32M | 64.89M | 58.75M | 29.30M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $543.06M | $696.15M | $161.41M | $108.50M | $104.27M |
| Short Term Investments | $1.75B | $1.16B | $483.53M | $468.56M | $336.47M |
| Cash and Short Term Investments | $2.29B | $1.85B | $644.94M | $577.05M | $440.74M |
| Net Receivables | $- | $1.25M | $4.67M | $5.93M | $6.39M |
| Inventory | $- | $- | $1 | $-12.72M | $- |
| Other Current Assets | $38.33M | $25.07M | $10.57M | $6.79M | $6.99M |
| Total Current Assets | $2.33B | $1.88B | $660.18M | $577.05M | $454.12M |
| Property Plant Equipment Net | $141.82M | $100.01M | $73.74M | $71.24M | $36.34M |
| Goodwill | $14.61M | $14.61M | $14.61M | $14.61M | $14.61M |
| Intangible Assets | $56.67M | $57.74M | $58.81M | $59.88M | $60.95M |
| Goodwill and Intangible Assets | $71.28M | $72.35M | $73.42M | $74.48M | $75.55M |
| Long Term Investments | $- | $- | $1.74M | $1.74M | $1.08M |
| Tax Assets | $- | $- | $26.26M | $27.97M | $19.43M |
| Other Non-Current Assets | $17.57M | $10.06M | $-23.40M | $-14.49M | $-19.13M |
| Total Non-Current Assets | $230.67M | $182.42M | $151.75M | $160.93M | $113.28M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $2.56B | $2.06B | $811.93M | $737.99M | $567.40M |
| Account Payables | $54.43M | $61.79M | $21.31M | $14.06M | $12.61M |
| Short Term Debt | $12.87M | $7.37M | $13.55M | $12.43M | $3.67M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $4.46M | $18.93M | $20.59M |
| Other Current Liabilities | $96.61M | $74.69M | $22.67M | $21.51M | $18.78M |
| Total Current Liabilities | $163.91M | $143.85M | $61.98M | $18.93M | $47.18M |
| Long Term Debt | $122.97M | $80.58M | $57.43M | $60.42M | $28.99M |
| Deferred Revenue Non-Current | $- | $- | $- | $6.57M | $8.48M |
| Deferred Tax Liabilities Non-Current | $2.35M | $3.12M | $7.03M | $7.44M | $7.44M |
| Other Non-Current Liabilities | $3.86M | $7.97M | $301.00K | $634.00K | $632.00K |
| Total Non-Current Liabilities | $129.18M | $91.66M | $64.76M | $116.49M | $45.55M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $293.10M | $235.51M | $126.74M | $135.42M | $92.72M |
| Preferred Stock | $- | $- | $- | $737.99M | $567.40M |
| Common Stock | $18.00K | $16.00K | $9.00K | $8.00K | $7.00K |
| Retained Earnings | $-1.74B | $-1.14B | $-701.34M | $-452.64M | $-265.55M |
| Accumulated Other Comprehensive Income Loss | $1.32M | $544.00K | $-1.78M | $-376.00K | $116.00K |
| Other Total Stockholders Equity | $4.00B | $2.96B | $1.39B | $1.06B | $740.10M |
| Total Stockholders Equity | $2.27B | $1.83B | $685.19M | $602.57M | $474.68M |
| Total Equity | $2.27B | $1.83B | $685.19M | $602.57M | $474.68M |
| Total Liabilities and Stockholders Equity | $2.56B | $2.06B | $811.93M | $737.99M | $567.40M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $2.56B | $2.06B | $811.93M | $737.99M | $567.40M |
| Total Investments | $1.75B | $1.16B | $483.53M | $468.56M | $336.47M |
| Total Debt | $135.84M | $87.94M | $64.20M | $66.63M | $32.66M |
| Net Debt | $-407.22M | $-608.20M | $-97.21M | $-41.86M | $-71.60M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $543.06M | $201.26M | $275.71M | $288.43M | $696.15M | $358.40M | $380.33M | $427.22M | $161.41M | $178.94M | $105.78M | $97.67M | $108.50M | $129.15M | $195.60M | $351.60M | $104.27M | $64.87M | $23.98M | $182.67M |
| Short Term Investments | $1.75B | $1.35B | $1.32B | $1.42B | $1.16B | $454.80M | $529.16M | $482.58M | $483.53M | $476.07M | $355.65M | $421.09M | $468.56M | $479.50M | $450.72M | $330.00M | $336.47M | $401.27M | $301.47M | $165.28M |
| Cash and Short Term Investments | $2.29B | $1.55B | $1.59B | $1.70B | $1.85B | $813.20M | $909.49M | $909.80M | $644.94M | $655.01M | $461.43M | $518.75M | $577.05M | $608.65M | $646.32M | $681.59M | $440.74M | $466.14M | $325.44M | $347.95M |
| Net Receivables | $- | $- | $- | $- | $1.25M | $309.00K | $2.51M | $4.00M | $4.67M | $4.94M | $5.62M | $5.38M | $5.93M | $7.41M | $6.53M | $7.56M | $6.39M | $9.30M | $7.33M | $8.45M |
| Inventory | $- | $- | $- | $- | $1 | $1 | $1 | $- | $1 | $1 | $- | $- | $-12.72M | $1 | $1 | $1 | $- | $- | $1 | $- |
| Other Current Assets | $38.33M | $29.66M | $34.02M | $25.66M | $25.07M | $10.96M | $10.09M | $8.96M | $10.57M | $30.31M | $31.98M | $10.21M | $6.79M | $14.94M | $16.32M | $15.19M | $6.99M | $4.18M | $7.61M | $5.69M |
| Total Current Assets | $2.33B | $1.58B | $1.62B | $1.73B | $1.88B | $824.47M | $922.09M | $922.75M | $660.18M | $675.11M | $483.05M | $534.34M | $577.05M | $623.54M | $661.01M | $697.40M | $454.12M | $482.90M | $340.38M | $362.09M |
| Property Plant Equipment Net | $141.82M | $99.15M | $100.59M | $99.89M | $100.01M | $73.41M | $73.45M | $72.84M | $73.74M | $74.53M | $73.34M | $71.63M | $71.24M | $35.34M | $36.67M | $37.57M | $36.34M | $35.23M | $35.99M | $15.24M |
| Goodwill | $14.61M | $14.61M | $14.61M | $14.61M | $14.61M | $14.61M | $14.61M | $14.61M | $14.61M | $14.61M | $14.61M | $14.61M | $14.61M | $14.61M | $14.61M | $14.61M | $14.61M | $14.61M | $14.61M | $14.61M |
| Intangible Assets | $56.67M | $56.94M | $57.20M | $57.47M | $57.74M | $58.01M | $58.27M | $58.54M | $58.81M | $59.08M | $59.34M | $59.61M | $59.88M | $60.14M | $60.41M | $60.68M | $60.95M | $61.21M | $61.48M | $61.75M |
| Goodwill and Intangible Assets | $71.28M | $71.55M | $71.81M | $72.08M | $72.35M | $72.61M | $72.88M | $73.15M | $73.42M | $73.68M | $73.95M | $74.22M | $74.48M | $74.75M | $75.02M | $75.29M | $75.55M | $75.82M | $76.09M | $76.35M |
| Long Term Investments | $- | $- | $3.03M | $3.03M | $3.03M | $2.39M | $2.59M | $1.74M | $1.74M | $- | $1.74M | $1.74M | $1.74M | $1.08M | $1.08M | $1.08M | $- | $- | $- | $- |
| Tax Assets | $- | $- | $-3.03M | $- | $26.89M | $-2.39M | $-2.59M | $-1.74M | $26.26M | $- | $-1.74M | $-1.74M | $27.97M | $-1.08M | $-1.08M | $-1.08M | $- | $- | $- | $- |
| Other Non-Current Assets | $17.57M | $13.16M | $11.30M | $4.16M | $7.03M | $13.74M | $5.29M | $4.51M | $-23.40M | $2.59M | $2.46M | $2.59M | $-14.49M | $1.35M | $1.35M | $1.39M | $1.39M | $1.12M | $1.50M | $658.00K |
| Total Non-Current Assets | $230.67M | $183.86M | $183.71M | $179.16M | $209.31M | $159.76M | $151.62M | $150.50M | $151.75M | $150.80M | $149.76M | $148.43M | $160.93M | $111.44M | $113.03M | $114.25M | $113.28M | $112.17M | $113.58M | $92.25M |
| Other Assets | $- | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $2.56B | $1.76B | $1.81B | $1.91B | $2.09B | $984.23M | $1.07B | $1.07B | $811.93M | $825.91M | $632.80M | $682.77M | $737.99M | $734.98M | $774.05M | $811.65M | $567.40M | $595.07M | $453.96M | $454.34M |
| Account Payables | $54.43M | $24.46M | $29.32M | $32.38M | $61.79M | $29.63M | $29.78M | $19.91M | $21.31M | $24.38M | $14.07M | $14.17M | $14.06M | $10.49M | $10.44M | $9.65M | $12.61M | $6.66M | $10.17M | $7.88M |
| Short Term Debt | $12.87M | $8.40M | $16.66M | $8.17M | $14.74M | $11.51M | $11.44M | $5.92M | $13.55M | $14.03M | $12.06M | $12.66M | $12.43M | $9.92M | $9.85M | $7.40M | $3.67M | $3.71M | $3.73M | $3.44M |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $-8.33M | $1 | $- | $49.68M | $42.21M | $1.43M | $4.46M | $9.69M | $9.69M | $11.43M | $18.93M | $12.66M | $8.34M | $9.96M | $20.59M | $13.11M | $14.58M | $16.40M |
| Other Current Liabilities | $96.61M | $78.01M | $59.35M | $53.18M | $67.33M | $44.40M | $36.84M | $27.37M | $22.67M | $25.17M | $27.73M | $19.19M | $21.51M | $18.82M | $17.18M | $16.75M | $18.78M | $18.91M | $15.26M | $13.80M |
| Total Current Liabilities | $163.91M | $110.86M | $105.33M | $93.72M | $143.85M | $85.54M | $78.06M | $54.63M | $61.98M | $73.27M | $63.54M | $57.46M | $18.93M | $51.89M | $45.80M | $43.76M | $47.18M | $42.38M | $43.74M | $41.51M |
| Long Term Debt | $122.97M | $78.31M | $79.08M | $79.86M | $80.58M | $57.09M | $57.54M | $57.68M | $57.43M | $58.18M | $58.92M | $59.58M | $60.42M | $26.83M | $27.57M | $28.29M | $28.99M | $29.67M | $30.34M | $7.40M |
| Deferred Revenue Non-Current | $- | $- | $-79.08M | $- | $-1 | $- | $- | $- | $- | $5.42M | $3.84M | $5.66M | $6.57M | $9.68M | $7.62M | $8.13M | $8.48M | $9.77M | $11.61M | $12.42M |
| Deferred Tax Liabilities Non-Current | $2.35M | $3.12M | $3.12M | $3.12M | $30.00M | $3.16M | $7.03M | $7.03M | $7.03M | $7.15M | $7.44M | $7.44M | $7.44M | $7.44M | $7.44M | $7.44M | $7.44M | $7.08M | $7.08M | $7.10M |
| Other Non-Current Liabilities | $3.86M | $4.41M | $2.06M | $6.20M | $7.97M | $982.00K | $252.00K | $1.69M | $301.00K | $471.00K | $219.00K | $1.63M | $634.00K | $932.00K | $608.00K | $1.44M | $632.00K | $1.09M | $691.00K | $589.00K |
| Total Non-Current Liabilities | $129.18M | $85.83M | $84.26M | $89.17M | $118.55M | $61.23M | $64.81M | $66.39M | $64.76M | $71.22M | $70.42M | $74.32M | $116.49M | $44.88M | $43.24M | $45.31M | $45.55M | $47.62M | $49.72M | $27.51M |
| Other Liabilities | $- | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $293.10M | $196.69M | $189.59M | $182.90M | $262.40M | $146.77M | $142.87M | $121.03M | $126.74M | $144.49M | $133.96M | $131.78M | $135.42M | $96.77M | $89.04M | $89.07M | $92.72M | $90.00M | $93.46M | $69.03M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $734.98M | $774.05M | $811.65M | $- | $595.07M | $453.96M | $454.34M |
| Common Stock | $18.00K | $16.00K | $16.00K | $16.00K | $16.00K | $11.00K | $11.00K | $11.00K | $9.00K | $9.00K | $8.00K | $8.00K | $8.00K | $8.00K | $8.00K | $8.00K | $7.00K | $7.00K | $6.00K | $6.00K |
| Retained Earnings | $-1.74B | $-1.54B | $-1.39B | $-1.25B | $-1.14B | $-976.17M | $-867.74M | $-769.44M | $-701.34M | $-644.83M | $-571.50M | $-510.28M | $-452.64M | $-399.96M | $-347.02M | $-302.72M | $-265.55M | $-231.34M | $-204.12M | $-176.91M |
| Accumulated Other Comprehensive Income Loss | $1.32M | $3.81M | $-1.86M | $-1.20M | $544.00K | $-871.00K | $-1.25M | $-556.00K | $-1.78M | $-2.42M | $-1.76M | $-1.28M | $-376.00K | $-40.00K | $9.00K | $63.00K | $116.00K | $211.00K | $291.00K | $36.00K |
| Other Total Stockholders Equity | $4.00B | $3.11B | $3.01B | $2.98B | $2.96B | $1.81B | $1.80B | $1.72B | $1.39B | $1.33B | $1.07B | $1.06B | $1.06B | $1.04B | $1.03B | $1.03B | $740.10M | $736.19M | $564.32M | $562.18M |
| Total Stockholders Equity | $2.27B | $1.57B | $1.62B | $1.73B | $1.83B | $837.46M | $930.84M | $952.22M | $685.19M | $681.42M | $498.84M | $550.99M | $602.57M | $638.20M | $685.01M | $722.58M | $474.68M | $505.07M | $360.50M | $385.32M |
| Total Equity | $2.27B | $1.57B | $1.62B | $1.73B | $1.83B | $837.46M | $930.84M | $952.22M | $685.19M | $681.42M | $498.84M | $550.99M | $602.57M | $638.20M | $685.01M | $722.58M | $474.68M | $505.07M | $360.50M | $385.32M |
| Total Liabilities and Stockholders Equity | $2.56B | $1.76B | $1.81B | $1.91B | $2.09B | $984.23M | $1.07B | $1.07B | $811.93M | $825.91M | $632.80M | $682.77M | $737.99M | $734.98M | $774.05M | $811.65M | $567.40M | $595.07M | $453.96M | $454.34M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $2.56B | $1.76B | $1.81B | $1.91B | $2.09B | $984.23M | $1.07B | $1.07B | $811.93M | $825.91M | $632.80M | $682.77M | $737.99M | $734.98M | $774.05M | $811.65M | $567.40M | $595.07M | $453.96M | $454.34M |
| Total Investments | $1.75B | $1.35B | $1.32B | $1.42B | $1.16B | $454.80M | $529.16M | $482.58M | $483.53M | $476.07M | $355.65M | $421.09M | $468.56M | $479.50M | $450.72M | $330.00M | $336.47M | $401.27M | $301.47M | $165.28M |
| Total Debt | $135.84M | $86.71M | $8.33M | $88.03M | $87.94M | $62.85M | $63.26M | $63.60M | $64.20M | $65.20M | $64.95M | $65.91M | $66.63M | $31.79M | $32.49M | $31.99M | $32.66M | $33.38M | $34.06M | $10.84M |
| Net Debt | $-407.22M | $-114.56M | $-267.38M | $-200.40M | $-608.20M | $-295.55M | $-317.07M | $-363.62M | $-97.21M | $-113.74M | $-40.83M | $-31.75M | $-41.86M | $-97.37M | $-163.11M | $-319.60M | $-71.60M | $-31.49M | $10.09M | $-171.83M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-600.09M | $-436.37M | $-248.71M | $-187.09M | $-108.16M |
| Depreciation and Amortization | $-43.50M | $9.31M | $9.66M | $7.33M | $6.54M |
| Deferred Income Tax | $- | $-3.91M | $-419.00K | $- | $-375.00K |
| Stock Based Compensation | $79.20M | $61.77M | $31.20M | $20.72M | $8.89M |
| Change in Working Capital | $406.00K | $36.75M | $-13.49M | $8.72M | $-8.30M |
| Accounts Receivables | $1.25M | $3.42M | $1.26M | $464.00K | $2.34M |
| Inventory | $- | $- | $- | $7.68M | $-2.34M |
| Accounts Payables | $-6.46M | $32.47M | $7.29M | $2.24M | $305.00K |
| Other Working Capital | $5.62M | $864.00K | $-22.03M | $-1.66M | $-8.61M |
| Other Non Cash Items | $6.55M | $-18.13M | $-2.64M | $3.13M | $1.34M |
| Net Cash Provided by Operating Activities | $-557.44M | $-350.57M | $-224.40M | $-147.18M | $-100.06M |
| Investments in Property Plant and Equipment | $-10.31M | $-7.73M | $-10.82M | $-6.53M | $-2.93M |
| Acquisitions Net | $- | $- | $13.30M | $135.59M | $231.30M |
| Purchases of Investments | $-2.14B | $-1.06B | $-612.77M | $-671.34M | $-544.13M |
| Sales Maturities of Investments | $1.59B | $724.05M | $599.47M | $535.75M | $312.83M |
| Other Investing Activities | $- | $-1 | $-13.30M | $-135.59M | $-231.30M |
| Net Cash Used for Investing Activities | $-554.39M | $-342.60M | $-24.12M | $-142.12M | $-234.23M |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $846.35M | $385.76M | $298.05M | $291.24M | $420.07M |
| Common Stock Repurchased | $5.03M | $3.32M | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $113.06M | $843.44M | $3.39M | $2.94M | $2.71M |
| Net Cash Used Provided by Financing Activities | $959.41M | $1.23B | $301.43M | $294.18M | $422.78M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $-152.42M | $536.03M | $52.91M | $4.88M | $88.48M |
| Cash at End of Period | $546.76M | $699.18M | $163.15M | $110.23M | $105.35M |
| Cash at Beginning of Period | $699.18M | $163.15M | $110.23M | $105.35M | $16.87M |
| Operating Cash Flow | $-557.44M | $-350.57M | $-224.40M | $-147.18M | $-100.06M |
| Capital Expenditure | $-10.31M | $-7.73M | $-10.82M | $-6.53M | $-2.93M |
| Free Cash Flow | $-567.74M | $-358.30M | $-235.22M | $-153.71M | $-103.00M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-194.57M | $-156.29M | $-133.23M | $-116.00M | $-161.54M | $-108.43M | $-98.30M | $-68.10M | $-56.51M | $-73.33M | $-61.22M | $-57.65M | $-52.68M | $-52.94M | $-44.30M | $-37.18M | $-34.20M | $-27.22M | $-27.21M | $-19.52M |
| Depreciation and Amortization | $3.39M | $66.00K | $2.80M | $2.76M | $2.86M | $2.15M | $1.77M | $2.53M | $2.60M | $2.43M | $2.33M | $2.29M | $2.06M | $1.75M | $1.84M | $1.68M | $1.70M | $1.63M | $1.67M | $1.54M |
| Deferred Income Tax | $- | $- | $- | $- | $-43.00K | $-3.87M | $- | $- | $-419.00K | $- | $- | $- | $- | $- | $- | $- | $359.00K | $- | $- | $-716.00K |
| Stock Based Compensation | $22.44M | $20.77M | $19.77M | $16.21M | $25.43M | $13.67M | $12.98M | $9.70M | $8.32M | $8.14M | $8.10M | $6.64M | $6.20M | $5.83M | $5.31M | $3.39M | $2.63M | $2.67M | $2.02M | $1.57M |
| Change in Working Capital | $42.02M | $13.13M | $-4.74M | $-47.21M | $21.20M | $-2.73M | $21.27M | $-2.95M | $-13.60M | $12.18M | $-4.95M | $-7.11M | $4.25M | $7.78M | $2.37M | $-5.67M | $4.25M | $-4.50M | $3.45M | $-11.51M |
| Accounts Receivables | $- | $- | $- | $1.25M | $-945.00K | $2.20M | $1.49M | $678.00K | $267.00K | $684.00K | $-241.00K | $546.00K | $1.48M | $-885.00K | $1.04M | $-1.17M | $2.91M | $-1.97M | $1.12M | $287.00K |
| Inventory | $- | $- | $- | $- | $-10.95M | $-1.64M | $12.59M | $- | $- | $- | $- | $- | $3.60M | $2.09M | $1.87M | $126.00K | $-1.34M | $- | $- | $- |
| Accounts Payables | $29.36M | $-2.79M | $-4.08M | $-28.96M | $24.30M | $580.00K | $8.63M | $-1.05M | $-1.51M | $10.24M | $-952.00K | $-492.00K | $2.57M | $189.00K | $1.61M | $-2.13M | $4.62M | $-3.37M | $2.14M | $-3.08M |
| Other Working Capital | $12.66M | $15.91M | $-660.00K | $-19.51M | $8.79M | $-3.87M | $-1.43M | $-2.58M | $-12.36M | $1.28M | $-3.76M | $-7.17M | $-3.41M | $6.38M | $-2.14M | $-2.49M | $-1.93M | $-1.13M | $1.31M | $-8.42M |
| Other Non Cash Items | $-11.57M | $-8.10M | $-12.77M | $33.12M | $-8.47M | $-1.28M | $-4.85M | $-3.58M | $-2.17M | $10.66M | $27.00K | $667.00K | $907.00K | $997.00K | $693.00K | $534.00K | $227.00K | $400.00K | $87.00K | $611.00K |
| Net Cash Provided by Operating Activities | $-138.29M | $-130.42M | $-128.17M | $-160.56M | $-120.56M | $-100.50M | $-67.12M | $-62.39M | $-61.79M | $-51.74M | $-55.72M | $-55.16M | $-39.27M | $-36.59M | $-34.08M | $-37.25M | $-25.03M | $-27.02M | $-19.99M | $-28.02M |
| Investments in Property Plant and Equipment | $-1.22M | $-3.52M | $-2.40M | $-3.17M | $-2.32M | $-2.54M | $-1.12M | $-1.76M | $-2.88M | $-3.52M | $-2.53M | $-1.89M | $-1.18M | $-454.00K | $-1.31M | $-3.58M | $-1.17M | $-687.00K | $-474.00K | $-603.00K |
| Acquisitions Net | $- | $- | $- | $- | $884.05M | $-79.89M | $42.42M | $-5.75M | $4.23M | $- | $-64.93M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-695.21M | $-364.88M | $-374.86M | $-701.68M | $-519.61M | $-170.04M | $-176.18M | $-193.10M | $-160.34M | $-212.96M | $-127.65M | $-111.82M | $-110.81M | $-168.25M | $-278.24M | $-114.04M | $-44.88M | $-194.05M | $-205.17M | $-100.04M |
| Sales Maturities of Investments | $303.53M | $346.93M | $485.20M | $456.88M | $141.52M | $249.93M | $133.75M | $198.85M | $156.11M | $93.05M | $192.58M | $157.73M | $120.53M | $138.53M | $156.76M | $119.93M | $108.99M | $93.77M | $69.14M | $40.92M |
| Other Investing Activities | $- | $- | $110.34M | $-244.80M | $-884.05M | $79.89M | $-42.42M | $5.75M | $-4.23M | $-119.91M | $64.93M | $45.91M | $9.72M | $-29.72M | $-121.47M | $5.89M | $64.11M | $-100.28M | $-136.02M | $-59.11M |
| Net Cash Used for Investing Activities | $-392.90M | $-21.47M | $107.94M | $-247.97M | $-380.40M | $77.35M | $-43.54M | $4.00M | $-7.10M | $-123.44M | $62.40M | $44.02M | $8.53M | $-30.18M | $-122.78M | $2.31M | $62.95M | $-100.97M | $-136.50M | $-59.72M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $772.05M | $74.29M | $7.50M | $810.00K | $2.55M | $1.01M | $62.05M | $323.71M | $49.92M | $248.13M | $495.00K | $305.00K | $10.10M | $319.00K | $-564.00K | $281.71M | $-34.00K | $167.80M | $-1.33M | $253.72M |
| Common Stock Repurchased | $- | $- | $3.16M | $- | $3.32M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-5.00K | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $101.75M | $3.00M | $7.50M | $810.00K | $839.35M | $1.01M | $2.58M | $499.00K | $1.44M | $209.00K | $1.43M | $305.00K | $632.00K | $319.00K | $868.00K | $555.00K | $1.49M | $1.08M | $86.00K | $27.00K |
| Net Cash Used Provided by Financing Activities | $873.80M | $77.29M | $7.50M | $810.00K | $839.35M | $1.01M | $64.63M | $324.20M | $51.36M | $248.34M | $1.43M | $305.00K | $10.73M | $319.00K | $868.00K | $282.26M | $1.49M | $168.88M | $-1.34M | $253.74M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $-640.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $342.61M | $-74.59M | $-12.72M | $-407.72M | $337.75M | $-22.13M | $-46.03M | $265.81M | $-17.53M | $73.16M | $8.11M | $-10.83M | $-20.00M | $-66.45M | $-156.00M | $247.33M | $39.40M | $40.90M | $-157.82M | $166.01M |
| Cash at End of Period | $546.76M | $204.15M | $278.74M | $288.43M | $696.15M | $360.79M | $382.92M | $428.96M | $163.15M | $180.68M | $107.52M | $99.40M | $110.23M | $130.24M | $196.68M | $352.68M | $105.35M | $65.95M | $25.06M | $182.88M |
| Cash at Beginning of Period | $204.15M | $278.74M | $291.46M | $696.15M | $358.40M | $382.92M | $428.96M | $163.15M | $180.68M | $107.52M | $99.40M | $110.23M | $130.24M | $196.68M | $352.68M | $105.35M | $65.95M | $25.06M | $182.88M | $16.87M |
| Operating Cash Flow | $-138.29M | $-130.42M | $-128.17M | $-160.56M | $-120.56M | $-100.50M | $-67.12M | $-62.39M | $-61.79M | $-51.74M | $-55.72M | $-55.16M | $-39.27M | $-36.59M | $-34.08M | $-37.25M | $-25.03M | $-27.02M | $-19.99M | $-28.02M |
| Capital Expenditure | $-1.22M | $-3.52M | $-2.40M | $-3.17M | $-2.32M | $-2.54M | $-1.12M | $-1.76M | $-2.88M | $-3.52M | $-2.53M | $-1.89M | $-1.18M | $-454.00K | $-1.31M | $-3.58M | $-1.17M | $-687.00K | $-474.00K | $-603.00K |
| Free Cash Flow | $-139.51M | $-133.94M | $-130.57M | $-163.73M | $-122.88M | $-103.03M | $-68.24M | $-64.15M | $-64.66M | $-55.26M | $-58.24M | $-57.05M | $-40.45M | $-37.04M | $-35.39M | $-40.83M | $-26.20M | $-27.71M | $-20.46M | $-28.62M |
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
$40.74
Stock Price
$7.57B
Market Cap
534
Employees
Redwood City, CA
Location
Revenue (FY 2024)
$-
-100.0% YoY
Net Income (FY 2024)
$-600.09M
-37.5% YoY
EPS (FY 2024)
$-3.58
7.3% YoY
Free Cash Flow (FY 2024)
$-567.74M
-58.5% YoY
Profitability
Gross Margin
0.0%
Net Margin
0.0%
ROE
-26.5%
ROA
-23.5%
Valuation
P/E Ratio
-12.23
P/S Ratio
0.00
EV/EBITDA
-10.05
Market Cap
$7.57B
Revenue & Net Income
Profit Margins
Cash Flow Summary
Operating Cash Flow
$-557.44M
-59.0% YoY
Free Cash Flow
$-567.74M
-58.5% YoY
Balance Sheet Summary
Total Assets
$2.56B
24.1% YoY
Total Debt
$135.84M
54.5% YoY
Shareholder Equity
$2.27B
-16.3% YoY
Dividend Overview
No Dividend Data
Revolution Medicines, Inc. doesn't currently pay dividends.
Revolution Medicines Dividends
Explore Revolution Medicines's dividend history, including dividend yield, payout ratio, and historical payments.
Revolution Medicines News
Read the latest news about Revolution Medicines, including recent articles, headlines, and updates.
Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting
Zoldonrasib, a RAS(ON) G12D-selective inhibitor, demonstrated acceptable tolerability and encouraging initial antitumor activity in patients with previously treated KRAS G12D mutant non-small cell lung cancer Zoldonrasib, a RAS(ON) G12D-selective inhibitor, demonstrated acceptable tolerability and encouraging initial antitumor activity in patients with previously treated KRAS G12D mutant non-small cell lung cancer
Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting
REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced 11 oral and poster presentations will be featured at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, held from April 25 – 30, 2025.
Revolution Medicines to Participate in April 2025 Investor Conferences
REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will participate in in two upcoming investor conferences.
Revolution Medicines, Inc. (RVMD) Q4 2024 Earnings Call Transcript
Revolution Medicines, Inc. (NASDAQ:RVMD ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Ryan Asay - Senior Vice President-Corporate Affairs Mark Goldsmith - Chairman and Chief Executive Officer Jack Anders - Chief Financial Officer Steve Kelsey - President-Research and Development Wei Lin - Chief Medical Officer Conference Call Participants Eric Joseph - J.P. Morgan Marc Frahm - TD Cowen Michael Schmidt - Guggenheim Ben Burnett - Stifel Laura Prendergast - Raymond James Jay Olson - Oppenheimer Joe Catanzaro - Piper Sandler Poorna Kannan - Needham & Company Alex Bouilloux - Barclays Bank Operator Good day, and thank you for standing by.
Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress
Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic cancer to enable expected data readout in 2026 Company is activating study sites for Phase 3 RASolve 301 trial of daraxonrasib in previously treated locally advanced or metastatic RAS mutant non-small cell lung cancer Company anticipates initiating two additional registrational trials of daraxonrasib in earlier lines of treatment for pancreatic cancer in the second half of 2025 Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif.
Revolution Medicines to Participate in March 2025 Investor Conferences
REDWOOD CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that Mark A.
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025
REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2024 on Wednesday, February 26, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and full year and provide an update on corporate progress.
Does Revolution Medicines (RVMD) Have the Potential to Rally 74.05% as Wall Street Analysts Expect?
The mean of analysts' price targets for Revolution Medicines (RVMD) points to a 74.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference
REDWOOD CITY, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will participate in a fireside chat as part of the Guggenheim Securities SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 10:30 a.m. ET.
Revolution Medicines (RVMD) Loses -7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Revolution Medicines (RVMD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will deliver a corporate presentation as part of the 43r d Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. PT.
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
Underwriters' full exercise of option brings gross proceeds to $862.5 million Underwriters' full exercise of option brings gross proceeds to $862.5 million
Revolution Medicines: Risky Buy On Recent Share Price Dip
Revolution Medicines' stock has surged over 30% since April, driven by promising clinical data for its lead asset, RMC-6236, targeting RAS-mutated cancers. RMC-6236 shows best-in-class efficacy in PDAC, with potential expansion into NSCLC and CRC, positioning it as a potential new standard of care. Despite a recent stock dip due to a $600m public offering, Revolution's robust cash position and promising pipeline offer significant long-term potential.
Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants
REDWOOD CITY, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the pricing of 14,130,436 shares of its common stock at a public offering price of $46.00 per share, before underwriting discounts and commissions, and, in lieu of shares of common stock, to certain investors, pre-funded warrants to purchase 2,173,917 shares of common stock at a public offering price of $45.9999, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants in the offering are to be sold by Revolution Medicines. In addition, Revolution Medicines has granted the underwriters a 30-day option to purchase up to an additional 2,445,652 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering are expected to be approximately $750.0 million before deducting underwriting discounts and commissions and other offering expenses, excluding any exercise of the underwriters' option to purchase additional shares and excluding the exercise of any pre-funded warrants. The offering is expected to close on December 5, 2024, subject to customary closing conditions.
Revolution Medicines Announces Commencement of Public Offering of Common Stock
REDWOOD CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it has commenced an underwritten public offering to sell up to $600.0 million of shares of its common stock. All of the shares of common stock are being offered by Revolution Medicines. In addition, Revolution Medicines intends to grant the underwriters a 30-day option to purchase up to an additional $90.0 million of shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will host an investor webcast to provide clinical updates from its RAS(ON) inhibitor portfolio.
Revolution Medicines to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will be a featured speaker at Guggenheim's Inaugural Healthcare Innovation Conference and the UBS Global Healthcare Conference.
Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024
REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the third quarter 2024 on Wednesday, November 6, 2024, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.
Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
Encouraging progression-free survival and overall survival profile Safety findings consistent with previously reported data, no new safety signals observed Investor webcast to be held Friday, October 25 at 12:00 p.m. Eastern Time (ET) REDWOOD CITY, Calif.
Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma
REDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the first patient has been dosed in RASolute 302, a Phase 3 registrational study of RMC-6236, a RAS(ON) multi-selective inhibitor, in patients with previously treated, metastatic pancreatic ductal adenocarcinoma (PDAC).
Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast
Pancreatic ductal adenocarcinoma (PDAC) data from RMC-6236 (RAS(ON) multi-selective inhibitor) and RMC-9805 (RAS (ON) G12D-selective inhibitor) monotherapy studies to be featured in two late-breaking presentations Pancreatic ductal adenocarcinoma (PDAC) data from RMC-6236 (RAS(ON) multi-selective inhibitor) and RMC-9805 (RAS (ON) G12D-selective inhibitor) monotherapy studies to be featured in two late-breaking presentations
Revolution Medicines, Inc. (RVMD) Q2 2024 Earnings Call Transcript
Revolution Medicines, Inc. (NASDAQ:RVMD ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Ryan Asay - Senior Vice President of Corporate Affairs Mark Goldsmith - Chairman and Chief Executive Officer Jack Anders - Chief Financial Officer Steve Kelsey - President of R&D Wei Lin - Chief Medical Officer Conference Call Participants Marc Frahm - TD Cowen Michael Schmidt - Guggenheim Eric Joseph - JPMorgan Jonathan Chang - Leerink Partners Chris Shibutani - Goldman Sachs Eliana Merle - UBS Alec Stranahan - Bank of America Kelly Shi - Jefferies Jay Olson - Oppenheimer Laura Prendergast - Raymond James Joseph Catanzaro - Piper Sandler Operator Good day and thank you for standing by. Welcome to Revolution Medicine's Q2 2024 Earnings Conference Call.
Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress
REDWOOD CITY, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended June 30, 2024, and provided an update on corporate progress.
Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024
REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the second quarter 2024 on Wednesday, August 7, 2024, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for RVMD.